JBM and Jacobson announce inter-group license agreement

JBM (Healthcare) Limited and Jacobson Pharma Corporation Limited announced a joint connected transaction concerning the 2025 Europharm License Agreement. Europharm, a wholly-owned subsidiary of Jacobson, will license a portion of its Factory to Europharm HK, a wholly-owned subsidiary of JBM, for HK$247,000 per month from December 1, 2025, to January 27, 2028. This arrangement follows the expiration of the 2020 License Agreement.

The estimated right-of-use asset value for Europharm HK under this agreement is approximately HK$6.19m. This transaction is considered a one-off connected transaction for JBM and a continuing connected transaction for Jacobson. The annual caps for aggregate license fees under similar agreements for Jacobson are HK$5.58m for the financial years ending March 31, 2026, and March 31, 2027, and HK$4.59m for the period ending January 27, 2028.

Mr. Sum Kwong Yip, Derek, a controlling shareholder and director of both companies, has a material interest in this transaction. The boards of both Jacobson and JBM, including independent non-executive directors, consider the terms fair, reasonable, and in the best interests of shareholders. They cited benefits such as rental income for Europharm and continuity of manufacturing operations for Europharm HK.